Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertapenem pharmacokinetics with thrice-weekly post-hemodialysis dosing in end-stage renal disease
NL-OMON34802Phase 4Active, not recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ertapenem in bacterial disease, sponsored by Franciscus Gasthuis & Vlietland. Primary endpoint: Pharmacokinetic model describing ertapenem plasma concentration-time curves. Started Dec 2010; status: active, not recruiting.
02
Drugs
ertapenem
03
Conditions
bacterial disease
Beyond the preview
Go deeper on NL-OMON34802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34802.